These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 15791520

  • 1. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
    Pelton SI, Stanley K, Yogev R, Fletcher CV, McIntosh K, Wiznia A, Nachman S, Pediatric AIDS Clinical Trials Group 338 Study Team.
    Clin Infect Dis; 2005 Apr 15; 40(8):1181-7. PubMed ID: 15791520
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Apr 15; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X, Podzamczer D, Moral I, Roset M, Arnaiz JA, Loncà M, Casiró A, Rosón B, Gatell JM, BestQol Study Group.
    Antivir Ther; 2004 Dec 15; 9(6):979-85. PubMed ID: 15651756
    [Abstract] [Full Text] [Related]

  • 7. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
    Cressey TR, Leenasirimakul P, Jourdain G, Tod M, Sukrakanchana PO, Kunkeaw S, Puttimit C, Lallemant M.
    J Antimicrob Chemother; 2005 Jun 15; 55(6):1041-4. PubMed ID: 15883177
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
    Boyd MA, Srasuebkul P, Khongphattanayothin M, Ruxrungtham K, Hassink EA, Duncombe CJ, Ubolyam S, Burger DM, Reiss P, Stek M, Lange J, Cooper DA, Phanuphak P.
    Antivir Ther; 2006 Jun 15; 11(2):223-32. PubMed ID: 16640103
    [Abstract] [Full Text] [Related]

  • 10. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C, Burri M, Shen Y, Rode R, Nadal D, Pediatric Infectious Disease Group of Switzerland, Swiss Mother and Child HIV Cohort Study (MoCHiV).
    Pediatr Infect Dis J; 2008 May 15; 27(5):431-7. PubMed ID: 18382386
    [Abstract] [Full Text] [Related]

  • 11. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial.
    Skowron G, Stein D, Drusano G, Melbourne K, Bilello J, Mikolich D, Rana K, Agosti JM, Mongillo A, Whitmore J, Gilbert MJ.
    J Infect Dis; 1999 Oct 15; 180(4):1064-71. PubMed ID: 10479132
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
    Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, Sangkote J, Bunyaprawit P, Horsakulchai M, Lange J, Cooper D, Phanuphak P, Ruxrungtham K.
    Antivir Ther; 2005 Oct 15; 10(2):301-7. PubMed ID: 15865224
    [Abstract] [Full Text] [Related]

  • 14. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
    Coplan PM, Cook JR, Carides GW, Heyse JF, Wu AW, Hammer SM, Nguyen BY, Meibohm AR, DiNubile MJ, AIDS Clinical Trials Group 320 Study Team.
    Clin Infect Dis; 2004 Aug 01; 39(3):426-33. PubMed ID: 15307012
    [Abstract] [Full Text] [Related]

  • 15. [Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients].
    Salmon-Céron D, Deleuze J, Coste J, Guerin C, Ginsburg C, Blanche P, Finkielsztejn L, Pecqueux L, Chaput S, Gorin I, Sicard D.
    Ann Med Interne (Paris); 2000 Jun 01; 151(4):297-302. PubMed ID: 10922958
    [Abstract] [Full Text] [Related]

  • 16. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B, Frankfurt HIV Cohort.
    J Antimicrob Chemother; 2006 Nov 01; 58(5):1024-30. PubMed ID: 16956902
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 01; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N, Müller A, Rottmann C, Lutz T, Klauke S, Kurowski M, Staszewski S, Harder S.
    Eur J Med Res; 2006 Jun 30; 11(6):236-44. PubMed ID: 16820336
    [Abstract] [Full Text] [Related]

  • 19. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE, Wasmuth JC, Fätkenheuer G, Schneider K, Schmitz K, de Boo TM, Reiss P, Hekster YA, Burger DM, Rockstroh JK.
    Antivir Ther; 2003 Aug 30; 8(4):309-14. PubMed ID: 14518700
    [Abstract] [Full Text] [Related]

  • 20. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
    Jankelevich S, Mueller BU, Mackall CL, Smith S, Zwerski S, Wood LV, Zeichner SL, Serchuck L, Steinberg SM, Nelson RP, Sleasman JW, Nguyen BY, Pizzo PA, Yarchoan R.
    J Infect Dis; 2001 Apr 01; 183(7):1116-20. PubMed ID: 11237839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.